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Introduction
The aim of the present document is to present the key facts and data of the Italian biotech industry, 
and to provide a brief analysis of the current context within which Italian companies are operating. 
The overall emerging picture relies on the statistic survey made, for the first time this year, by Assobiotec 
and ENEA on those biotech firms which were active in Italy as of year-end 2015, also based on the 
analysis of their 2014 balance sheets and on estimates of future trends expected. 
Moreover, the said core analysis was integrated with data from the National Statistical System or other 
public data, thus providing additional snapshots on the entire Italian biotechnology industrial sector.
In fact, as an integral part of the National Statistical Programme and the basis for the biotech indu-
stry OECD structural statistics, the 2016 Assobiotec - ENEA survey provides our Stakeholders with 
detailed insights not only on the many scientific and applicative aspects connected to Italian biotech 
companies’ operations, but also on their innovation drive on the entire industrial system in Italy. 
Particular attention was paid this year to the analysis of the incidence of biotech R&D activities, in the 
strict sense, in order to have a better understanding of their objective contribution on the broader R&D 
commitment of Italian biotech firms.
What definitely stands out is the fact that the more biotech R&D is done, the higher the total R&D 
commitment is. 
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•  The Italian biotech industry has undergone through an extraordinary 
growth due to several factors, among them being the undisputed excel-
lence of our academic and industrial research, and the ability of Italian 
companies to turn innovation into valuable products and technologies.
•  Almost 500 biotech companies were active in Italy at the end of 2015, 
covering all fields of application. Over half of these (256) are dedicated 
biotech R&D firms that devote more than 75% of their total R&D 
investment to research activities relating to biotechnologies.
•  The large majority of Italian biotech companies (75%) are micro or small-
sized organisations. This share moves to 90% when only considering 
the dedicated biotech R&D companies, which are indeed the driving 
force for the entire Italian biotech industry.
•  Total biotech turnover exceeds 9.4 billion euro; R&D investment makes 
over 1.8 billion euro, while the number of biotech employees is above 
9,200 units. 
•  Biotechnology is a high research-intensive industry: among the Italian 
capital dedicated biotech R&D firms, the incidence of biotech R&D in-
vestment on turnover is 25%, with peaks up to 40% for many of them. 
•  Also in Italy, Red biotech is the spearhead segment of the entire sector, with 
261 companies actively developing innovative therapeutic and diagnostic 
products, 7.1 billion euro revenues, and 1.4 billion euro R&D investment. 
•  With reference to the project portfolio of 77 Italian capital companies, 
the Italian biotech therapeutic pipeline accounts, altogether, for 249 
projects, 190 of which have already reached the preclinical (53%) or 
clinical (33%) phases. 
•  Although biotechnologies also apply to the identification and develop-
ment of chemical synthesis active principles, more than 40% of the 
R&D projects relate to biopharmaceuticals, such as monoclonal antibo-
dies, recombinant proteins, vaccines and Advanced Therapy Medicinal 
Products (ATMPs). Most of these projects fall within therapeutic areas 
which apply to a number of unmet medical needs or are becoming 
increasingly relevant, due to the overall aging of the population. 
•  Rare Disease and Advanced Therapy Medicinal Products are among the 
areas of excellence of Italian research. Not by chance, the first Advanced 
Therapy treatment approved in the Western-world is an ATMP product 
based on stem cells, developed by an Italian biotech company.
•  Somehow connected to human health biotechnology are also the emer-
ging areas of GPET (Genomics, Proteomics and Enabling Technologies), 
with 65 companies which are mainly active in the field of big data, thus 
contributing to accelerating the transition to Personalized Medicine. 
Red biotech and GPET 
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1. Executive summary
•  With regard to Green biotechnology, a large majority of the 44 companies, which are active 
in this specific area, are micro dedicated biotech R&D firms (73%) engaged in a variety of 
projects aimed at exploiting the potential of agro-biotechnology, by improving the nutritional 
value of animal and plant productions, as well as the sustainability of the Italian food chain.
•  Industrial biotechnology has to do with the use enzymes, originated by bacteria, fungi and 
algae, in a diversity of application areas, including the retrain of conventional industrial 
processes, the production of energy and bioproducts, environment bioremediation and the 
restoration of the artistic heritage. About half of the 119 firms active in the White Biotech 
segment, are dedicated biotech R&D firms exploiting biotechnologies for the conversion of 
natural renewable biomass into sustainable biochemicals and biofuels. 
•  Indeed, Italian Green Chemistry enjoys a true competitive edge, at a world level, in terms 
of technological leadership in the production processes of biolubricants, colours, solvents, 
detergents, pesticides, bioplastics, natural fibres and other materials with highly innovative 
features, which are already now a viable alternative to traditional petrochemical products.
•  Bioeconomy, as a model for smart, sustainable and inclusive growth, based on the conversion 
of renewable natural resources into building blocks for materials, chemicals and energy, is an 
established reality in Italy too, which worths about 244 billion euro and provides work for more 
than 1.5 million people.
Green biotech, White biotech  
and the Bioeconomy 
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1. Executive summary
•  In a direct comparison between the biotechnology and the manufacturing industries in Italy 
 –  the share of R&D employees is 5 times higher among biotech R&D firms, and 13 
times higher among Italian capital dedicated biotech R&D firms;
 –  the share of intra-muros R&D expenditure is 2.3 times higher among biotech 
R&D firms, and 14 times higher among Italian capital dedicated biotech R&D 
firms.
•  The Italian biotech firms enjoy the highest levels of educational attainment, with 73% of 
graduate employees on total employees. Something to be reckoned with, in order to 
 –  avoid jeopardizing the massive training investment Italy supports through its 
University; 
 –  to offer our best talents adequate employment and professional growth 
opportunities; 
 –  to compete with the other EU member States in attracting skills and investments 
 –  to make of our Country a winning system in the arena of the most advanced 
knowledge-based economies.
•  As such, the Italian biotech industry can truly play a key role in spreading innovation and in 
enhancing the competitiveness of the entire Italian industrial system.      
A high research-intensive industry
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Values in thousands of euros €/000
Total biotech R&D 
investment
503,813 186,300381,296




Dedicated biotech  
R&D firms…
… of which, Italian capital 
dedicated biotech R&D firms
7ENEA - Industry and Business Associations Unit April 2016 • Centro Studi Assobiotec®
2. The Italian biotech industry in figures
… mirror the dynamism of a 
steadily growing industry
•  Almost 500 biotech companies were active in Italy at the end of 2015. Over half of these 
(256) are firms that devote more than 75% of their total R&D investment to research 
activities relating to biotechnologies and, as such, dedicated biotech R&D firms.
•  Total biotech turnover exceeds 9.4 billion euro; total R&D investment* makes over 1,8 
billion euro, while the number of biotech employees is above 9,200 units. 
•  Within the biotech activities of the Italian capital dedicated biotech R&D firms, the incidence 
of the R&D investment on turnover equals 25%**, with peaks up to 40% for some of them.
* intra-muros plus extra-muros 
**Total biotech R&D investment on biotech turnover 
82. The Italian biotech industry in figures
 A high research-intensive industry
Also in Italy, biotechnology is a high research-intensive industry, compared to the whole industrial sector.  
In a direct comparison with the manufacturing industry,
•  the share of R&D employees is 5 times higher 
among biotech R&D firms, and 13 times higher 
among Italian capital dedicated biotech R&D firms;
•  the share of intra-muros R&D expenditure on overall 
turnover*, is 2.3 times higher among biotech R&D 
firms, and 14 times higher among Italian capital 
dedicated biotech R&D firms.
*Overall turnover means the sum of total revenues of Italian biotech firms, including incomes originating from other business activities. In this sense, the Italian 






























R&D employees on total employees
Intra-muros R&D investment on overall 
turnover
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Source:  
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2. The Italian biotech industry in figures
The evolution of the biotech industry 
in Italy
The Italian biotech industry has undergone through an extraordinary growth due to several 
factors, among them being the undisputed excellence of our academic and industrial research, 
and the ability of Italian companies to turn innovation into valuable products and technologies.







Number of biotech firms in Italy
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Companies covering all fields 
of applications …
Most of the Italian biotech firms are active in healthcare biotechnology (53%). Others are 
engaged in industrial biotechnology (24%), in GPET - Genomics, Proteomics and Enabling 
Technologies (13%) and in Green biotechnology, including agriculture and livestock (9%).
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… in order to meet a number of key 
challenges
•  Identifying and developing therapeutics, vaccines, cosmetics, drug discovery and drug 
delivery technologies, molecular diagnostic methods. More than half of Italian biotech 
companies (261) are active in the Red biotech field.
•  Converting biomass into bio-based sustainable products and second-generation biofuels; 
improving the efficiency and environmental sustainability of conventional production 
processes; bioremediation, restoration and … much more. Almost a quarter (119) of Italian 
biotech companies are active in the White biotech field. 
•  Analysing the structure and function of genes and proteins; developing bioinformatics 
technologies; production of biochips and biopharmaceuticals; accelerating the transition to 
Personalized Medicine. There are 65 companies in Italy, which are active in GPET, with a 
majority in the field of big data.
•  Improving the nutritional value of animal and plant production; increasing agricultural 
productivity without extending cultivable land; reducing water consumption; preventing the 
attacks of pests and plant disease; protecting animal health care. There are 44 companies 
in Italy, which are active in the Green biotech field. 
2. The Italian biotech industry in figures
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2. The Italian biotech industry in figures
•  Almost 75% of Italian biotech 
companies are micro or small-
sized organisations.
•  This percentage is even higher 
for GPET companies.
•  Almost 50% of micro-sized 





16% 25%18% 11% 17%
15% 9%7% 2% 10%
52% 50%64% 82% 58%
18% 16%11% 6% 14%





Biotech firms:  




Micro: < 10 employees
Small: < 50 employees
Medium: 50 - 250 employees
Big: > 250 employees
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2. The Italian biotech industry in figures
•  Almost 90% of the dedicated biotech R&D 
firms are micro or small-sized organisations, 
with the only exception of those which are 
active in the Red biotech segment, where 
17% of dedicated biotech R&D firms are 
medium or big-sized organizations. 
•  More than 50% of micro-sized firms are 
spin offs.
18% 27%17% 9% 17%
5% 0%2% 0% 3%
66% 73%76% 86% 72%
12% 0%5% 5% 8%
WhiteRed Green GPET Total
Dedicated biotech R&D firms: 
analysis by size













Micro: < 10 employees
Small: < 50 employees
Medium: 50 - 250 employees
Big: > 250 employees
2. The Italian biotech industry in figures
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Lombardy 29.43% 51.11%141 28.83%
Friuli - Venezia Giulia 4.22% 0.18%25 5.11%
Piedmont 6.61% 3.25%57 11.66%
Campania 2.34% 0.48%23 4.70%
Emilia - Romagna 2.90% 1.92%44 9.00%
Sardinia 0.55% 0.03%13 2.66%
Marche 0.70% 0.90%10 2.04%


















Tuscany 39 7.98% 23.31% 12.16%
Trentino - Alto Adige 12 2.45% 0.54% 1.33%
Liguria 5 1.02% 8.10% 0.03%
1.97%
100.00%
Veneto 38 7.77% 1.97% 1.89%
0.68%
100.00%









Operational headquarters: geographic distribution
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2. The Italian biotech industry in figures
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•  Lombardy is the first Region in Italy by number of companies, R&D 
investments and biotech sales, followed by: Piedmont and Latium 
for number of companies; Tuscany and Latium for intra-muros R&D 
investment; Latium and Tuscany for biotech sales.
•  Considering the average biotech revenues per company, Latium ranks 
first, Lombardy second and Tuscany third. It is interesting to note that 
the fourth and fifth position are those of two emerging Regions: 
Basilicata and Trentino Alto Adige.
> 15% 
< 1% 
5% - 15% 







1% - 10% 
20% - 50%
10% - 20% 
< 1%
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Biotech turnover: analysis by 
application field
•  Considering the total number of firms, those 
active in the Red biotech field generate 
more than 75% of total turnover.
•  The evolution of the turnover at three and 
five years, shows significant increases 
in almost all fields of application, thus 
confirming the contribution to the Italian 
biotech industry development of the many 
new products and technologies that are 
reaching the market, as well as the anti-
cyclical nature of this business. 
Total companies: breakdown of turnover by field of application
Biotech turnover: forecast by field of application








Forecast 2017* Forecast 2019*
12.8% 18.1%Total
GPET









Biotech turnover: Italian capital and foreign 
invested firms
•  The Italian biotech industry turnover amounts to 9.4 billion euro, 3.8 billion of which originate from dedicated 
biotech R&D firms. Although accounting for 14% of total companies, foreign invested firms contribute to 78% 
of total sales.
•  Among the Italian capital companies, 80% of turnover originates from those which are active in the Red biotech field.
















Foreign invested firms Red GreenWhite GPET
Dedicated biotech R&D firms: breakdown of turnover 
between Italian capital and foreign invested firms
Italian capital dedicated biotech R&D firms: 
breakdown of the turnover by field of application





•  Based on ISTAT foreign trade data, we were able to 
trace 175 exporting companies (36% of total biotech 
firms in Italy); in 2014, their overall exports amounted 
to 12.6 billion euro. 
•  Exports of biotech products, in the strict sense, totalled 
691 million euro, almost half of which (52%) originate 




































































































































































































































tra il 10% e il  20%
tra il 5% e il  10%
tra l’1%  e il  5%
tra lo 0,5%  e l’1%
tra lo 0%  e lo 0,5%
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2. The Italian biotech industry in figures
Source: elaboration on ISTAT data, 2014
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tra il 10% e il  20%
tra il 5% e il  10%
tra l’1%  e il  5%
tra lo 0,5%  e l’1%
tra lo 0%  e lo 0,5%
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Exports analysis by field of application, dimension  
and company type 






















































38%Dedicated biotech R&D firms
2. The Italian biotech industry in figures
•  Red and Green biotech are the two sectors originating the greater exports in the entire Italian biotech industry.
•  The share of exporting firms increases with the company size, and is far below the average in micro-sized organisations.
•  The portion of dedicated biotech R&D firms with export activities is greater in all fields of application – with the only 
exception of the Green biotech field – and it doesn’t directly relate to the size of the organization.
•  All of the medium and big-sized dedicated biotech R&D firms are exporting companies; with specific reference to those 
which are active in the Green area, almost all of the small-sized organisations are exporting companies too.
Source: elaboration on ISTAT data
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Net income 
•  Almost 63% of Italian biotech 
companies recorded a profit 
in 2014. The said percentage 
is intrinsically limited by the 
net financial results of the 
dedicated biotech R&D firms, 
most of which are micro or 
small-sized organisations that 
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Total firms
470







2. The Italian biotech industry in figures
Values in thousands of euros €/000
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Financing sources by kind
•  With reference to 2014, the majority (56%) of Italian biotech companies has been 
self-financing its activities, more than a quarter (26%) had access to private or public 
grants, almost 16% has resorted to debt capital, while only 4% could access risk capital. 
•  Besides proving the weakness of the Italian equity market, the above data highlight the 
key role which government funding plays in supporting new research intensive entrepre-
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2. The Italian biotech industry in figures
Analysis of the different sources of financing to which companies have resorted in 2014, in order to fund their activities 
*A representative sample of firms
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Global biotech Venture Capital 
investment
•  The entire venture capital market remains underdeveloped in Italy. Indeed, total capital 
invested in 2015, with reference to the 11 transactions regarding the biotech sector, 
amounts 7.3 million euro*.
•  However, in recent years, several Italian biotech firms generated agreements for a total 
























In 2015, private biotech raised 12.2 billion USD,  
up 32% from 9.2 billion USD in 2014
Values in million USD $/000,000 Source: BCIQ - BioCentury Online Intelligence 




•  The large majority (63%) of Italian capital dedicated biotech R&D 
firms attributes a high strategic value to the possibility of reaching a 
partnership or a co-development agreement with third party companies. 
•  Similarly, about half of them considers as relevant, or as extremely rele-
vant, the possibility to integrate their project portfolio through in-licensing 
agreements (41%), or to generate profits through out-licensing deals 
(43%). 
 
•  On the contrary, only a minority of the same firms would be open both to 
conferring their assets in a possible joint venture (33%) with a third party 
company (16%), or to seeking for an M&A transaction (5%).
•  There seems to be tendency to maintain within the original organization 
the control and the exploiting of the available know-how and expertise, 
that is typical of small-sized firms or of those entrepreneurial initiatives 
originating from academic spin offs, at least in their initial phases. 
Italian capital dedicated biotech R&D firms: *different potential strategic options in terms of relevance






Acquisition of new technologies and products
Strategic options 
Share of firms, which considers as relevant or as 
extremely relevant the given strategic options
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•  Research is the growth engine of any economic system. 
•  According to a recent report from the European Commission* 
 –  those EU Countries that have invested in innovation, 
knowledge and growth of business skills, could better 
overcome the crisis;
 –  adequate investments in research and technological 
innovation are behind the higher levels of productivity of the 
leading European economies. 
•  This is why Italy too needs to support research, and biotechnology 
research in particular.
•  Not by chance, the European Union has included biotechnologies 
among the Key Enabling Technologies, based on their potential impact 
and retrain on a broad number of industrial sectors. 
•  With specific reference to the SME instrument in Horizon 2020, Italy 
ranks first in terms of number of proposals submitted, and among the 
top three EU Countries, along with Spain and the United Kingdom, in 
terms of number of funded proposals. 






















R&D expenditure in 1994 (% of GDP)
















0.5 1.0 1.5 2.0 2.5
*Total Factor Productivity
Source: The drivers of Total Factor Productivity in catching-up  
economies – DG ECFIN 2014
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3. R&D activities
R&D investment 
•  Considering total companies, the share of biotech R&D 
investment amount to 27% of total R&D investments. 
•  The said share increases to 91% when only 
considering the dedicated biotech R&D firms, and 
reaches 96% with regards to the Italian capital 
dedicated biotech R&D firms. 
•  Based on the estimates provided by the companies 
themselves, the intra-muros biotech investment will 
grow on average by 2.7% per year, with peaks of 
up to 5.3% for those firms which are active in the 
Green biotech segment.
* A representative number of firms
Intra-muros biotech R&D investment
Total biotech R&D investment
Total intra-muros R&D investment

















Values in thousands of euros €/000 - Investments 2014
Total  
firms
Dedicated biotech  
R&D firms 
… of which, Italian capital  
dedicated biotech R&D firms
Extra-muros biotech R&D investment 51,597 8,10715,607
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3. R&D activities
Values in thousands of euros €/000 - R&D investment in 2014














Total firms Total firms Total firms Total firms
GPET







































Total intra-muros R&D  
investment
Intra-muros biotech R&D 
investment
Extra-muros biotech R&D 
investment
Total extra-muros R&D  
investment
Total R&D investment
Total biotech R&D investment
28
Public policy measures to support R&D
•  In 2014, more than 50% of companies could benefit from at least one form of public policy 
support for their R&D activities.
•  Considering the tax credit mechanism on R&D costs enacted by the Italian Government, de-
spite having only had feedback from a limited number of companies, we can reasonably state 
that in 2014 the Italian biotech firms were granted a deduction of at least 16 million euro on 
their taxable incomes.
•  About one third of these companies intend to make use of the aforesaid tax credit also in 
2015. 
Central government administration
Regional and local  
government administration








Capital account and  
interest account grants
Operating grants, tax credits  
and tax bonuses
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A representative sample of firms
3. R&D activities
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R&D employees on total employees
In line with what has been observed for the incidence of R&D investments on turnover, also 
the share of biotech R&D employees on total employees is significantly higher in the case of 
dedicated biotech R&D firms, out of total firms.



































Highly qualified job opportunities
•  With only 49% of graduate employees on total employees, Italy is 
lagging behind in Europe in terms of educational attainment in the 
science-based industry.
•  With 73% of graduate employees, on total employees*, the Italian 
biotech industry ranks well above the European average (67%).
•  The Italian biotech industry enjoys the highest levels of educational 
attainment. Something to be reckoned with, in order to avoid jeopardizing 
the massive training investment Italy supports through its University, to 
offer our best talents adequate opportunities in terms of professional 
growth, to compete with the other EU member States in attracting skills 
and investments, to make of our Country a winning system in the arena 
of the most advanced knowledge-based economies. 
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*A representative sample of firms
Graduate employees on total employees in the science-based sectors.
Elaboration on Eurostat data: Human Resources in Science and Technology, 2014

































































































































































Values in thousands of euros €/000
49,995 4,2648,968
Red biotech
Total firms Dedicated biotech  
R&D firms…
 … of which, Italian capital 




In the case of the Italian capital dedicated biotech R&D firms, the incidence of 
research investment on their revenues or operating costs reaches on average 
25% 
32
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4. Red biotech
Answering to the growing 
healthcare demand of an ageing 
population
•  Also in Italy, human health biotechnology is the spearhead segment of the entire biotech 
sector. 
•  Indeed, the majority (53%) of biotech companies are Red biotech firms that represent a 
major share of total biotech turnover (75%), as well as of total biotech R&D investment 
(90%) and biotech R&D employees (79%). 
•  Based on our analysis, we identified 261 biotech firms engaged in the research and 
development of new therapeutic and diagnostic tools, at the end of 2015.
•  Of these, 131companies are dedicated biotech R&D firms that devote 75% or more of their 
total R&D costs to biotech activities.
33
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4. Red biotech
•  By tracing the project portfolio of 77 Italian capital companies* it emerges that the Italian 
biotech therapeutic pipeline accounts, altogether, 249 projects, 190 of which have already 
reached the preclinical (53%) or clinical (33%) development phases.
•  We also identified five (5) additional Phase I and II clinical projects, which will be directly 
developed by the big pharma companies to whom they were sold, together with other 20 
projects which originate from the Italian capital pharmaceutical companies biotech R&D 
activities.
*We only counted the Italian capital companies, net of pharmaceutical companies. 
As such, the number of the above projects is only partial, compared to the number 
of biotech products developed entirely in Italy.
Therapeutics:  



























•  Italian companies’ investments are mainly focused on 
those therapeutic areas that are still associated to a 
number of unmet medical needs (i.e.: oncology and 
immunology), or are becoming increasingly relevant, 
both from an epidemiological and clinical point of 
view, due to the overall aging of the population (i.e.: 
neurology).
•  The emergence of infectious disease, such as 
HIV/AIDS and tuberculosis, or the resurgence 
of epidemics such as that associated with the 
Ebola virus, also directs investments towards the 
development of vaccines for the prophylaxis and 
prevention of possible pandemics. 
Respiratory diseases 
Oncology




Inflammatory and autoimmune diseases 
Cardiovascular diseases and haematology 
Metabolic, hepatic and endocrine diseases
Dermatology 
Gastrointestinal diseases 
Preclinical Phase I Phase II Phase III
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Project analysis by therapeutic area and phase of development
The WHO has selected an Italian vaccine to tackle the epidemic of Ebola
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4. Red biotech
•  More than 40% of the R&D projects relates to biopharmaceuticals: monoclonal antibodies, recombinant 
proteins, vaccines and Advanced Therapy products – half of which are still in preclinical phase – that open a 
radically new perspective for the treatment of a number unmet medical needs and Rare Disease. 
•  Biotechnological methods are also applied for the identification and development of new active principles of 
chemical synthesis, such as small molecules and peptides. 
•  Most of the ongoing trials (44%) relates to the 
development of monoclonal antibodies for the 
treatment of cancer, whilst 24% of the studies regards 
the development of recombinant proteins for curing 
oncological, infectious and metabolic diseases.
The growing share of biopharmaceuticals














Project analysis by type











•  Seven (7) are the Italian biotech companies that 
have obtained at least one Orphan Drug Designation 
(ODD); five (5) of these therapies are already in 
Phase III clinical development.
•  Two (2) are the theranostic products, for the diagnosis 
and treatment of medium intestine neuroendocrine 
tumours; the relevant applications for Marketing 
Authorization have already been applied both to the 
FDA and the EMA. 
•  Of the 29 Advanced Therapy projects, eight (8) are already in clinical development phase.
•  One (1) additional ATMP product, developed by Telethon and acquired by GSK, for the 
treatment of ADA-SCID, a severe form of immunodeficiency disease, has completed clinical 
development and is now expected to be registered by the EMA.
Rare Disease and Advanced Therapy Medicinal Products (ATMPs) are among the areas of excellence of Italian research. On the one 
hand, our academic scientists enjoy the largest number of scientific publications in the field of Rare Disease; on the other, the first ATMP 
product approved in the Western world is a product based on stem cells, developed by an Italian biotech company.














3 7 6 16
2 3 0 5
0 2 1 3
4 0 0 4
10 12 7 29




1 0 0 1
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4. Red biotech
•  The innovation drive of biotechnologies has been also exploited in 
diagnostics, leading to the development of new detective, quantitative 
and predictive methods, that by accurately and promptly identifying the 
causes of disease, allow both the correlation between diagnosis and 
therapeutic schemes specifically customized on patient’s characteristics, 
and the steady monitoring of therapy in terms of effectiveness. 
•  This specifically applies to the so-called omics technologies, which 
have made a dramatic contribution to the identification of biomarkers 
that can be used to establish a patient population eligible for a specific 
treatment, or to forecast the adverse effects on another, or like litmus 
paper for therapy monitoring. 
•  In this perspective also falls the growing interest in theranostics, one of 
the most advanced border of oncological research, based on the use of 
magnetic nanoparticles coated with a polymer and bonded to antibodies 
that can be used both for the early detection of cancer cells and for their 
destruction.
•  Among the projects developed by the 60 diagnostic firms we could 
identify in the course of our analysis, we counted as many as six (6) 
theranostic peptides and one (1) monoclonal antibody for oncological 
indications. 
Improved diagnostics for 
better treatments
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•  The sequencing of the human genome, the understanding of the genetic and molecular 
bases of the disease, and the countless tools provided by biotechnologies allow the industry 
to develop innovative therapeutic approaches, selectively aimed at specific pharmacologi-
cal targets, as well as to anticipate their effects on a particular patient population and to 
optimize the entire pathway of cure.
•  Having consolidated a number of therapeutic approaches aimed at large populations of 
patients, modern medicine is now moving towards the establishment of a new paradigm of 
Personalized Medicine, based on a variety of patient-specific models, or directed at specific 
subsets of patients’ populations. 
•  We are therefore facing a radical change of perspective, the development of which relies 
on the fundamental progresses in the field of Advanced Therapy and Regenerative Medi-
cine, as well as on a number of diagnostic achievements with an incredible predictive and 
prognostic value. 
•  With regard to Regenerative Medicine, we could also count an increasing number of pro-
ducts that, from a regulatory point of view, would not properly fall under the definition of 
Advanced Therapy Medicinal Products, but rather under that of Medical Devices. Among 
these, it is worth mentioning 15 products, based on the use of specific human, animal or 
biosynthetic scaffolds, enriched with growth factors and patient stem cells, to be applied 
for tissue regeneration.
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5. Green biotech
Number of firms












Dedicated biotech  
R&D firms …
 … of which, Italian capital 
dedicated biotech R&D firms
Biotech employees
Total biotech R&D investment
897 162162
Biotech turnover 592,906 40,27040,270
R&D employees 223 7474
3,288 196196Total employees
In the case of Italian capital dedicated biotech R&D firms, the incidence of 
research investment on biotech revenues equals 11% 
40
ENEA - Industry and Business Associations Unit April 2016 • Centro Studi Assobiotec®
5. Green biotech
•  Continuous growth in food demand at a worldwide level, limited availability of water 
and cultivable land, protection of the ecosystem and its biodiversity, sustainability of the 
agricultural productions, food safety: these are just a few of the main issues of global 
agriculture we currently need to address.
•  Through biotechnology we can sequence the genome of the different plant varieties, protect 
crops from pests or increase their adaptability to the environment, reduce chemical and 
energy inputs, improve the nutritional profile of food and agricultural products.
•  Italian green biotech companies are actively engaged in increasing the nutritional value of 
animal and plant productions and in developing new diagnostic tools to ensure safety and 
wholesomeness of our products. 
•  Since ancient times, the growth of agricultural productivity has been driven by innovation in 
agronomic sciences and genetic improvement, and it shall continue to be so, also thanks 
to the new breeding techniques made available by biotechnology. 
Innovating in the agrifood chain
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6. White biotech
Values in thousands of euros €/000 
White biotech







Total companies Dedicated biotech R&D companies 
Biotech employees 1,352 326
Biotech turnover 1,642,815 85,576
R&D employees 1,633 251
22,188 975Total employees
Total biotech R&D investment
In the case of Italian capital dedicated biotech R&D firms, the incidence  
of research investment on biotech revenues equals 16% 
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6. White biotech
•  Industrial biotechnology has to do with the use of natural or engineered enzymes, 
originated by bacteria, fungi and algae, in a diversity of application areas ranging from the 
improvement of many industrial processes and the production of energy and bioproducts, 
up to environment bioremediation, and the restoration and conservation of the artistic 
heritage.
•  Indeed, a number of white biotech methods allow an increased performance of traditional 
industrial processes, with considerable advantages in terms of high added-value 
productions and economic and environmental sustainability.
•  Europe produces over 60% of the enzymes used in the food, pharmaceutical, nutraceutical, 
cosmeceutical, animal feed, paper, textile, chemical, wood processing and energy industries. 
•  Not surprisingly, the OECD estimates that currently more than 35% of products for daily use 
originate from biotechnologies.
The key role of microorganisms  
and enzymes
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7. The Bioeconomy 
From the conversion of renewable biomass ...
... to a new economic model of sustainable growth
•  In the European vision, the conversion of renewable natural resources 
into building blocks for materials, chemicals and energy, combines 
with a model of smart, sustainable and inclusive growth, to support 
economic recovery and generate new and qualified job opportunities.
•  The Bioeconomy is an established reality in Italy, which allowed the 
conversion of dismissed industrial plants into advanced biorefineries, 
whose strong integration with the agricultural districts from which the 
biomass comes, is the basic prerequisite to optimize the quality of the 
productions and to maximize the economic and environmental benefits 
for those territories. 
•  Measuring the value of the Bioeconomy in Italy, as well as its 
development prospects, is the focus of the Second Report on the 
Bioeconomy in Europe, issued by the Studies and Research Department 
of IntesaSanpaolo, in collaboration with Assobiotec .
•  The use of molecular biology techniques is more and more entering 
into the common practice for the selection of enzymes that can convert 
organic biomass into building blocks of biological origin and energy, as 
well as to retrain several traditional production processes in terms of 
greater efficiency and environmental sustainability.
•  Italian Green Chemistry, with its modern bio-refineries, looks at 
biotechnologies as an innovative and competitive way to produce 
biochemicals such as biolubricants, colours, solvents, detergents, 
pesticides, bioplastics, natural fibres and other materials with highly 
innovative features, which are already now a viable alternative to 
traditional petrochemical products. 
•  Facilities such the advanced biorefineries of BioChemtex in Crescentino, 
of Matrica in Porto Torres, of GFBiochemicals in Caserta, of Mater 
Biotech in Adria represent, by far, the new paradigm for the growth of 
Green Chemistry at a worldwide level.




The Bioeconomy: value of production in 2013 
In terms of production, Bioeconomy in Italy worths about 244 billion euro, equal 
to 7.9% of the total value of national production
Italy Germany France UK Spain
Agricolture, forestry  
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The Bioeconomy: employment  
opportunities in 2013 
In terms of employment, Bioeconomy in Italy provides work for more than 1.5 million people
Italy Germany France UK Spain EUS
Agricolture, forestry  






































































Source: Intesa Sanpaolo estimates, based on Eurostat dataValues in thousands of units
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The Bioeconomy: exports in 2013 
The value of Italian exports generated by the sectors belonging to Bioeconomy 
amounts to about 51 billion euro, representing almost 13% of total exports
Italy Germany France UK Spain EUS
Agricolture, forestry  






































































Bioeconomy of total 13.0 % 20.1 % 21.6 % 14.0 %6.6 % 9.6 %
Source: Intesa Sanpaolo estimates, based Eurostat dataValues in thousands of units




•  The national scenario is rapidly evolving, with a number of promising 
facts and initiatives for the development of the Italian biotech industry 
too. Among others, it is worth quoting the following ones: 
  –  the recognition of the status of innovative start-up and 
innovative SME;
  –  the introducing of a stable tax credit mechanism on R&D 
costs and investments;
  –  the adoption of a system of preferential taxation on intellectual 
property incomes (Patent Box);
  –  the implementing of several activities in order to support 
new entrepreneurial projects in the Life Sciences area: the 
Panakès VC fund and other seeding initiatives such as Italian 
Angels for Biotech and Italian Angels for Growth, together with 
specific accelerating programmes such as BiovelocITA, Open 
Accelerator and the Bioupper platform, just to quote a few; 
  –  the allocation of dedicated resources to finance a three-year 
plan, to boost genetic improvement in agriculture; 
  –  the increasing awareness of the importance of actively 
promoting the Italian innovation system also in the field of 
Life Sciences (Invest in Italy Global Roadshow).
  Not forgetting the unique opportunity the Human Technopole project 
offers Italian research. 
ENEA - Industry and Business Associations Unit April 2016 • Centro Studi Assobiotec®
48
9. Methodology
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•  The BioInItaly 2016 survey originates from the collaboration between Centro Studi Assobiotec and the Industry and Business Associations Unit - 
Contracts and Partnerships Management Directorate of ENEA.
•  All data and information were collected through a questionnaire sent to the companies active in the sector (response rate 41%), and by analysing the 
available balance sheets and corporate websites.
Companies have been classified according to the OECD (Organisation for Economic Co-operation and Development) methodology * based on the 
following definitions:
•  With reference to the field of application in which falls the predominant part of the company’s biotech activities, biotech firms are 
classified as follows:
 –  Biotechnology: the application of science and technology to living 
organisms, as well as parts, products and models thereof, to alter living 
or non-living materials for the production of knowledge, goods and 
services
 –  Biotech firm: a firm that is engaged in biotechnology by using at least 
one biotech technique to produce goods or services and/or to perform 
biotech R&D. Some of these firms may be large, with only a small 
share of total economic activity attributable to biotechnology
 –  Dedicated biotech R&D firm: a firm that devote 75% or more of 
their total R&D to biotechnology R&D
 –  Red biotech firms: companies operating in the human health 
sector, by using modern biotechnological methods for the research, 
development and production of products for the diagnosis, treatment 
and disease prevention, including drugs, new therapies, vaccines, 
diagnostics and molecular pharming.
 –  Green biotech firms: companies operating in agriculture and 
livestock, thus using modern biotechnological methods in order to 
improve animal and crop production, by increasing their productivity 
and quality, by fostering their adaptability to the environment and their 
resistance to pathogens, or by developing biological and eco-friendly 
products for the protection of plants and animals;
 –  White biotech firms: companies using modern biotechnological 
methods for the retraining of many conventional industrial processes and 
the conversion of renewable biomass into bioproducts and energy, as well 
as for applications in the food, nutraceutical and cosmeceutical industry, 
for the improvement of diagnostic and environmental remediation systems, 
or the development of products for the restoration of the artistic heritage; 
 –  Genomics, Proteomics and Enabling Technologies firms 
(GPET): companies applying modern biotechnological methods in the 
fields of the omics disciplines (genomics, proteomics, transcriptomics, 
etc.), bioinformatics technologies, systems biology, biochips, biosensor 
and basic research.
*OECD Biotechnology Statistics 2009
49
10. Italian biotech companies
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•  3 C.I. srl
• 4Lab Diagnostics srl
• A. Costantino & C. spa
• AAT Advanced Analytical 
• Technologies srl




• Aboca spa 
• Accelera srl
• ACS Dobfar spa




• Applications Italy srl
• Advent srl
• AEP Polymers srl
• Aethia srl
• Agri New Tech srl
• Agrifutur srl
• Agritest srl
• Agroalimentare Sud spa
• Agroils Technologies spa
• Agrolabo spa
• Alexion Pharma Italy srl
• Alga&Zyme Factory srl






• Also Biotech srl
• Altergon Italia srl
•  AMBC Advanced Molecular 





• Ananas Nanotech srl
• Angelini ACRAF spa
• Anika Therapeutics srl
• Apavadis Biotechnologies srl
• Aptenia srl 
• Aptuit srl
• Apulia Biotech scrl
• Archimede R&D srl
• Ardis srl
• Areta International srl
• Ariad Pharmaceuticals Italia srl





• BASF Italia srl
• Baxalta srl
• Baxter World Trade Italy srl
• Bayer Cropscience srl
• Bayer spa
• BBA Biotech srl
• Beta Renewables spa
• BGT Italia Biogenomic
• Technology srl
• Bict srl
• Bio 3 Research srl
• Bio Fab Research srl
• Bio Genetix srl
• Bio Merieux Italia spa
• Bio Soil Expert srl
• Bio Tools srl
• Bioaesis srl
• Bioagro srl
• Biocell Center spa













• Biomedical Research srl
• Biomedical Tissues srl
• Biomolecular Research
• Genomics srl










• Bioscience Genomics srl





• Biotec Sys srl 
• Biotecgen srl
• Bioteck srl
• Biotecnologie BT srl
• BioTekNet scpa
• Biouniversa srl
• Bio-Ve-Oil Olimpo srl
• Boehringer Ingelheim Italia spa
• Bracco Imaging spa
• Bristol Myers Squibb srl
• BSA Ambiente srl
• BSL Cosmetics srl
• BTM Biological Tools for
• Mediterranean Agricolture srl
• BTS Italia srl
• C4T scarl
• C5-6 Italy srl
• Cage Chemicals srl
• CCS Aosta srl





• Cereal Docks spa
• Chemi spa
• Chemical Center srl
• Chiesi Farmaceutici spa
• Chrono Benessere srl
• Clonit srl
• Clovis Oncology Italy srl
• CO.PRO.B. - Cooperativa
• Produttori Bieticoli sca
• Cogep srl 
• Colorobbia Italia spa
• Congenia srl
•  Consorzio Interdisciplinare 
di Studi Biomolecolari ed 
Applicazioni Industriali scrl
•  Consorzio Interuniversitario di 
Ricerca in Chimica dei Metalli 
nei Sistemi Biologici
•  Consorzio per il Centro di 
Biomedicina Molecolare scrl
•  Consorzio per la Genetica 
Molecolare Umana
• Corion Biotech srl
• CPC Biotech srl
• Crabion srl
• Creabilis Therapeutics srl




• Cypraea pscrl 
• DAC srl






• Diatech Pharmacogenetics srl
• Diatheva srl
• Dicofarm spa
•  Diesse Diagnostica Senese 
spa
• DIVAL Toscana srl
• DNA Analytica srl
• Dompe’ Farmaceutici spa
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• Dott. Dino Paladin - CRS








•  Ephoran Multi Imaging 
Solutions srl
• Epi C srl
• Epigen Therapeutics srl
• Epinova Biotech srl
• Epitech Group srl
• Eridania Sadam spa
• Erydel spa
• Espikem srl









• Exenia Group srl





• Farma ID srl
• Fastest srl
• Fastissues srl
• Fatro spa 
• Fem2 - Ambiente srl
•  Ecobioservices and Researches 
srl
• Ecoil srl
• Fidia Farmaceutici spa
• Fin-Ceramica Faenza spa
•  FIS - Fabbrica Italiana Sintetici 
spa
• Flora Conservation srl
• Flowmetric Europe srl
• Fly Life srl
•  Food Research and Innovation 
- FRI srl
•  Fotosintetica & Microbiologica 
srl
• Franvax srl
•  Fresenius Medical Care Italia 
spa 
• G&Life spa
• Galatea Bio Tech srl
• Galileo Research srl
• Geltis srl
• Genedia srl
• Genenta Science srl
• Generon srl










• Gentras snc 
• Genzyme srl
• Gexnano srl
• GF Biochemicals spa
• Gilead Sciences srl 
• Gio.Eco srl
• Giotto Biotech srl
• Glaxosmithkline spa
• Glaxosmithkline Vaccines srl
• Glures srl
• Glyconova srl
• Gnosis Bioresearch srl
• Gnosis spa
• Godiagnostics srl
• Green Lab srl
• Greentech srl
• Grape srl





• Hospira Italia srl
• HPF Nutraceutics srl
• Hygeia Lab srl
• IGA Technology Services srl








•  Integrated Systems 
Engineering srl
• IOM Ricerca srl
• IPADLAB srl
• Ipsen spa
•  IRB Istituto di Ricerche 
Biotecnologiche spa
•  IRBM - Istituto di Ricerche 
di Biologia Molecolare P. 
Angeletti spa
•  ISB - Ion Source & 
Biotechnologies srl
•  Istituto Biochimico Italiano 
Giovanni Lorenzini spa
•  Istituto di Ricerche Biomediche 
Antoine Marxer RBM spa




• Janssen Cilag spa





• Kos Genetic srl
• Kron Morelli srl
• Ktedogen srl
•  L.A.V. Laboratorio Analisi 
Veterinarie srl
• Labor srl
• Laboratori Turval Italia srl
• Lati Industria Termoplastici spa
• Lay Line Genomics spa
• LB Lyopharm srl
• Lead Discovery Siena srl
• LEBSC srl
• Lesaffre Italia spa
• Life and Device srl
• Life Line Lab srl
•  Lifegene sas di Lanza 




•  Lundbeck Pharmaceuticals 
Italy spa
• Mac Pharma srl
• Magis Lab srl
• Mater Biotech spa
• Matrica spa
• Mavi Sud srl
•  Medestea Research & 
Production spa
• Mediapharma srl
• Medical Research Institute srl 
• Mediteknology srl
• Menarini Biotech srl
• Merck Serono spa
• Merial Italia spa
• Meristema srl 
• Metagenics Italia srl
• Micro Biological Survey srl
• Micro4you srl
• Microbiol snc 
• Microbion srl
• Microbiotec srl
• Microgem srl 
• Microgenomics srl
• Micron Research Service srl
• Microspore spa
• Microtech srl
• Mindseeds Laboratories srl
10. Italian biotech companies
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10. Italian biotech companies
• ML Biotech Italia srl
• M-Medical srl
• Molecular Biotechnology srl
• Molirom srl
• Molmed spa
• Molteni Therapeutics srl
• Monsanto Agricoltura Italia spa
• Monteresearch srl
• MSD Italia srl
• Multimedica Holding spa
• Mybasol srl
• Mybatec srl
•  Mycoplast di Federico Maria 
Grati e Stefano Babbini snc
• Naicons scrl







• Natimab Therapeutics srl
• Natural Technologies Italia srl
• Naxospharma srl
• Nealys srl
• Need Pharma srl
• Neotica srl 
• Neotron spa
• Nerviano Medical Sciences srl
• Neuheart srl
•  Neuro Visual Science 
Technology srl
• Neuro-Zone srl
• Newron Pharmaceuticals spa
• Newronika srl
• Next Genomics srl
• NGB Genetics srl
• Nicox Research Institute srl
• Nobil Bio Ricerche srl





• Novartis Farma spa






• Officina Biotecnologica srl
• Olon spa
• Ophera srl
• Orphan Europe Italy srl
• Oxi.Gen Lab srl
• Patheon Capua spa
• Personal Genomics srl













• Principium Europe srl
• Probiotical spa
• Proge Farm srl





•  Recordati Industria Chimica e 
Farmaceutica spa
• REDD srl 
• Reithera srl
• Remembrane srl
• Research & Innovation spa
•  Research Toxicology Centre spa
• Resindion srl





• Rottapharm Biotech spa
•  S.I.F.I. Società Industria 
Farmaceutica Italiana spa
•  S.P.A. - Società Prodotti 
Antibiotici spa
• Sacace Biotecnologies srl
• Sacchetto spa
• Sacco srl
• SAFAN Bioinformatics sas 
• Salentec srl
• Sandoz Industrial Products spa
• Sanofi Aventis spa
• Sanofi Pasteur MSD spa
•  Sclavo Diagnostics 
International srl
•  Sea Marconi Technologies di 
Vander Tumiatti sas
• Sentinel CH spa
• Serge Genomics srl
• SetLance srl
• Shire Italia spa
• Shoreline Società Cooperativa
• Sigea srl
•  Sigma-Tau Industrie 
Farmaceutiche Riunite spa
• Silicon Biosystems spa
• Silk Biomaterials srl
• Sirius Biotech srl
• Smile Biotech srl
• Società Italiana Sementi spa
•  Società Metropolitana Acque 
Torino spa
• Società Produttori Sementi spa
• Sooft Italia spa
• Spaceland Italia srl
• Spider Biotech srl
• Spike Renewables srl




• Syngenta Italia spa
• Takeda Italia spa
• Takis srl
• Target Heart Biotec srl
• Technogenetics srl
• Tecna srl
• Tecnobios Procreazione srl
• Tectronik srl
• Telea Biotech srl
• Tensive srl
• Tes Pharma srl
• Tethis spa




•  Toma Advanced Biomedical 
Assays spa
• TOR srl 
• Transactiva srl
• Trustech srl
• Tydock Pharma srl
• UB-Care srl




• UPMC Italy srl
• Veneto Nanotech scpa
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